The Latest Breaking News from Acadia

Here's a roundup of top developments in the biotech space over the last 24 hours:

HC Wainwright says that a negative AdCom vote on Acadia Pharmaceuticals Inc&#

FDA experts voted against Acadia Pharmaceuticals' Alzheimer's disease psychosis drug, leading ACAD stock to plummet.

Here's a roundup of top developments in the biotech space over the last 24 hours:

HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected.

Ahead of Acadia Pharmaceuticals Inc's (NASDAQ:ACAD) FDA AdComm meeting on Friday, the agency officials released their briefing documents, revealing a mixed bag of opinions. The company's resubmitted supplemental New Drug Application for pimavanserin for hallucinations and delusions associated with Alzheimer's disease psychosis (ADP) has a target action date of August 4. Initially, the FDA…

There were no surprises in the FDA's assessment of an Alzheimer's drug from Acadia Pharmaceuticals, and ACAD stock surged Wednesday.

Acadia Healthcare stock is the IBD Stock Of The Day, as the country's leading behavioral services provider looks to build on its strong first-quarter earnings.

Here's a roundup of top developments in the biotech space over the last 24 hours.

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from a Phase 2 trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery. 

When Michelin started awarding stars to Chicago restaurants in 2011, the city was one of the most exciting places to eat in America. Grant Achatz had recently opened his evolving restaurant concept, Next, and chefs like Laurent Gras and Graham Elliot were cooking wildly ambitious dishes. It was the country’s…